What does radiotracer activity in the salivary glands and physiologic myocardial uptake on a technetium‑99m sestamibi parathyroid scan indicate when the parathyroid area shows only faint sestamibi uptake?

Interpretation of Sestamibi Scan Findings in Parathyroid Imaging

The radiotracer activity in your salivary glands and physiologic myocardial uptake represent normal biodistribution of technetium-99m sestamibi, while the faint parathyroid uptake suggests either a small parathyroid adenoma, multiglandular disease, or a false-negative scan that warrants additional imaging.

Understanding Normal Sestamibi Biodistribution

Technetium-99m sestamibi is a cationic complex that accumulates in viable myocardial tissue and is cleared primarily through the hepatobiliary system 1. The findings you're describing reflect the expected physiologic behavior of this radiotracer:

Expected Normal Uptake Patterns

• Myocardial uptake: Sestamibi naturally concentrates in the heart muscle (1.2% of injected dose at rest, 1.5% during exercise), with a biological half-life of approximately 6 hours 1
• Salivary gland activity: Normal physiologic uptake occurs in salivary glands as part of the tracer's biodistribution pattern
• Thyroid uptake: When using dual-tracer techniques, thyroid visualization is expected with pertechnetate or I-123

Interpreting Faint Parathyroid Uptake

The faint sestamibi uptake in the parathyroid region is concerning and requires careful interpretation, as it may represent:

Most Likely Explanations

1. Small parathyroid adenoma: Sensitivity of sestamibi imaging decreases significantly with smaller adenomas (sensitivity ranges from 24% to 66% for small lesions) 2

2. Masked uptake: Retained radionuclide in adjacent thyroid or submandibular gland tissue can obscure parathyroid lesions 2

3. Multiglandular disease (MGD): Parathyroid hyperplasia shows reduced sestamibi sensitivity compared to single adenomas 2

4. Technical factors affecting detection: The scan's sensitivity is influenced by:

   • Lesion volume (larger lesions are more readily detected) 3
   • Histopathological architecture (solid growth patterns show better uptake than diffuse hyperplasia) 3
   • Anatomical position (upper quadrant lesions have higher miss rates) 3
   • Oxyphilic cell content and vascularity 4

Critical Pitfalls to Avoid

Common Interpretation Errors

• Assuming negative scan excludes disease: Even with faint uptake, parathyroid pathology may be present, particularly in MGD where sensitivity drops from 71% to 64% 2

• Overlooking medication interactions: P-glycoprotein substrates (amlodipine, atorvastatin, telmisartan) can significantly reduce tracer uptake, causing false-negative results 5

• Missing ectopic locations: Parathyroid adenomas can occur in unexpected sites like the parapharyngeal space 6

When Symmetric Uptake Mimics Normal Thyroid

Be particularly cautious when bilateral parathyroid enlargement creates homogeneous uptake that resembles normal thyroid tissue 7. In such cases:

• Visual interpretation alone may be misleading
• Semiquantitative assessment of tracer washout is essential
• Normal thyroid tissue shows faster washout (26% ± 12%) compared to parathyroid tissue (15% ± 8%) 8

Recommended Next Steps

Enhanced Imaging Protocol

Given the faint uptake, proceed with SPECT/CT imaging if not already performed, as it significantly improves sensitivity:

• SPECT/CT increases sensitivity from 70% (planar alone) to 86% 2
• Provides precise anatomic localization 2
• Better differentiates parathyroid from thyroid lesions

Complementary Imaging

If sestamibi remains inconclusive:

1. Ultrasound parathyroid: Pooled sensitivity of 76-80%, particularly useful for concomitant thyroid evaluation 2

2. 4-D parathyroid CT: Comparable sensitivity (79%) to sestamibi with SPECT/CT (80%) when combined 2

3. Dual-tracer subtraction technique: Adding pertechnetate or I-123 thyroid scan improves sensitivity to 93% with SPECT/CT 2

Biochemical Correlation

Review these parameters that affect scan sensitivity:

• Serum calcium levels (mild hypercalcemia reduces sensitivity) 2
• Vitamin D levels 4
• PTH levels (consider bilateral internal jugular venous PTH sampling if multiple lesions suspected) 9

Special Considerations

If concomitant thyroid disease is present, the addition of CT to dual-tracer SPECT increases sensitivity from 80% to 94% 2. The sensitivity of sestamibi imaging is notably decreased by nodular thyroid disease 2.

For potential parathyroid carcinoma: Be aware that malignant parathyroid lesions can be sestamibi-negative while benign adenomas are positive 9. High ipsilateral internal jugular PTH with negative sestamibi should raise suspicion for carcinoma.